Literature DB >> 15561890

Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.

Carmen Choi1, Mathias Witzens, Marianna Bucur, Markus Feuerer, Nora Sommerfeldt, Andreas Trojan, Anthony Ho, Volker Schirrmacher, Hartmut Goldschmidt, Philipp Beckhove.   

Abstract

Multiple myeloma (MM) is one of the most common hematologic malignancies. Despite extensive therapeutical approaches, cures remain rare exceptions. An important issue for future immunologic treatments is the characterization of appropriate tumor-associated antigens. Recently, a highly glycosylated mucin MUC1 was detected on a majority of multiple myeloma cell lines. We analyzed bone marrow and peripheral blood of 68 patients with HLA-A2-positive myeloma for the presence and functional activity of CD8 T cells specific for the MUC1-derived peptide LLLLTVLTV. Forty-four percent of the patients with MM contained elevated frequencies of MUC1-specific CD8 T cells in freshly isolated samples from peripheral blood (PB) or bone marrow (BM) compared with corresponding samples from healthy donors. BM-residing T cells possessed a higher functional capacity upon specific reactivation than PB-derived T cells with regard to interferon gamma (IFN-gamma) secretion, perforin production, and cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15561890     DOI: 10.1182/blood-2004-01-0366

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.

Authors:  Philipp Beckhove; Rolf Warta; Britt Lemke; Diana Stoycheva; Frank Momburg; Martina Schnölzer; Uwe Warnken; Hubertus Schmitz-Winnenthal; Rezvan Ahmadi; Gerhard Dyckhoff; Mariana Bucur; Simone Jünger; Thomas Schueler; Volker Lennerz; Thomas Woelfel; Andreas Unterberg; Christel Herold-Mende
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma.

Authors:  Vito Racanelli; Patrizia Leone; Maria Antonia Frassanito; Claudia Brunetti; Federico Perosa; Soldano Ferrone; Franco Dammacco
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

Review 3.  Post-transplant adoptive T-cell immunotherapy.

Authors:  Nicole A Aqui; Carl H June
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

4.  Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.

Authors:  Christoph Reissfelder; Slava Stamova; Christina Gossmann; Marion Braun; Andreas Bonertz; Ute Walliczek; Mario Grimm; Nuh N Rahbari; Moritz Koch; Maral Saadati; Axel Benner; Markus W Büchler; Dirk Jäger; Niels Halama; Khashayarsha Khazaie; Jürgen Weitz; Philipp Beckhove
Journal:  J Clin Invest       Date:  2014-12-22       Impact factor: 14.808

5.  Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer.

Authors:  Seyer Safi; Yoshikane Yamauchi; Anchana Rathinasamy; Slava Stamova; Martin Eichhorn; Arne Warth; Geraldine Rauch; Hendrik Dienemann; Hans Hoffmann; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2017-09-08       Impact factor: 8.110

Review 6.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.

Authors:  Eva Rossmann; Anders Österborg; Eva Löfvenberg; Aniruddha Choudhury; Ulf Forssmann; Anja von Heydebreck; Andreas Schröder; Håkan Mellstedt
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy.

Authors:  Maud Condomines; Jean-Luc Veyrune; Marion Larroque; Philippe Quittet; Pascal Latry; Cécile Lugagne; Catherine Hertogh; Tarik Kanouni; Jean-François Rossi; Bernard Klein
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422

10.  Quantification of the CD8+ T cell response against a mucin epitope in patients with breast cancer.

Authors:  Konrad Kokowski; Ulf Harnack; David C Dorn; Gabriele Pecher
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-03-31       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.